Sarmen Sarkissian, MD As reported at the ASCO 2018 meeting in Chicago, Migden et al report on athe results of the PD-1 targeting monoclonal antibody cemiplimab. was testing in a phase 1/2 clinical trial in patients with locally advanced and metastatic cutaneous squamous cell carcinoma of the skin. 26 patients in the phase 1 and 59 patients in the phase 2 trial were evaluated. All patients received 3mg/kg every 2 weeks. ORR was seen in 50% in the phase 1 and 47% in phase 2. 57% of patients [...]
